title: A novel modular polymer platform for the treatment of head and neck squamous cell carcinoma in an animal model.
abstract: OBJECTIVE
  To evaluate the therapeutic efficacy of a novel modular polymer platform in the treatment of head and neck squamous cell carcinoma (HNSCC).
  
  
  METHODS
  In vivo study.
  
  
  METHODS
  Academic research laboratory. Subjects and
  
  
  METHODS
  C3H/HeJ mice and SCID/beige mice were randomized to receive implantation of no polymer, plain polymer, plain polymer with local cisplatin injection, or cisplatin polymer. The 2 groups of mice implanted with cisplatin polymer or no polymer were further randomized to receive 4 Gy of external beam radiation for 4 days or no radiation. Tumor size was measured until the mice were humanely killed. At necropsy, the tumors were excised and weighed.
  
  
  RESULTS
  There was a significant reduction in tumor growth using this novel polymer platform. The cisplatin-secreting polymer effectively reduced human head and neck tumor growth in SCID mice by 17-fold and SCC VII/SF tumors in C3H/HeJ mice by more than 16-fold compared with the control, plain polymer, and plain polymer + intratumoral cisplatin injection groups (P = .01 for both). We also observed a statistically significant lower tumor weight in mice treated with cisplatin polymer and concomitant radiation compared with the radiation alone and control groups.
  
  
  CONCLUSIONS
  We demonstrate the efficacy of a novel polymer platform in delivering cisplatin to a partially resected SCC in a murine model. This polymer may represent a new therapeutic modality for patients with HNSCC. Once this polymer platform is optimized, we will plan for validation in the context of a prospective trial in patients with unresectable advanced or recurrent HNSCC.
authors.affiliation: Division of Head and Neck Surgery, Department of Surgery, Jonsson Comprehensive Cancer Center, USA.
authors.forename: David
authors.initials: D
authors.lastname: Hu
authors.forename: Ontario D
authors.initials: OD
authors.lastname: Lau
authors.forename: Linda
authors.initials: L
authors.lastname: Wang
authors.forename: Guanyu
authors.initials: G
authors.lastname: Wang
authors.forename: Dorthe
authors.initials: D
authors.lastname: Schaue
authors.forename: Li
authors.initials: L
authors.lastname: Zhu
authors.forename: Min
authors.initials: M
authors.lastname: Huang
authors.forename: Yuan
authors.initials: Y
authors.lastname: Lin
authors.forename: Miranda
authors.initials: M
authors.lastname: Dennis
authors.forename: Elliot
authors.initials: E
authors.lastname: Abemayor
authors.forename: David A
authors.initials: DA
authors.lastname: Elashoff
authors.forename: Steven M
authors.initials: SM
authors.lastname: Dubinett
authors.forename: William H
authors.initials: WH
authors.lastname: McBride
authors.forename: Sherven
authors.initials: S
authors.lastname: Sharma
authors.forename: Ben
authors.initials: B
authors.lastname: Wu
authors.forename: Maie A
authors.initials: MA
authors.lastname: St John
mesh_terms: D000818:Animals; D001672:Biocompatible Materials; D002208:Caproates; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000532:radiotherapy; D002945:Cisplatin / Q000008:administration & dosage* / Q000494:pharmacology; D004195:Disease Models, Animal; D004343:Drug Implants; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy; D007783:Lactones; D051379:Mice; D016513:Mice, SCID; D011091:Polyesters; D011108:Polymers; D011897:Random Allocation
chemical_list: D001672:Biocompatible Materials; D002208:Caproates; D004343:Drug Implants; D007783:Lactones; D011091:Polyesters; D011108:Polymers; C121056:caprolactone; C062968:lactide-caprolactone copolymer; D002945:Cisplatin